Vorapaxar - Wikipedia
Late Breaking Clinical Trials: CORONARY (On-Pump vs. Off-Pump CABG), CPORT (Nonprimary PCI Without Surgical Backup), ASCERT (CABG vs. PCI), and TRAP2-TIMI 50 (Vorapaxar for... | tctmd.com
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
Vorapaxar | CAS:618385-01-6 | PAR-1 antagonist,potent and orally active | High Purity | Manufacturer BioCrick
Zontivity (vorapaxar) for the Reduction of Thrombotic Cardiovascular Events - Clinical Trials Arena
Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial - The Lancet HIV
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events – A Review on Vorapaxar - ScienceDirect
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction | tctmd.com
Vorapaxar - Wikipedia
Vorapaxar - an overview | ScienceDirect Topics
APExBIO - Vorapaxar|PAR-1 antagonist,potent and orally active|CAS# 618385-01-6
Vorapaxar phase III program. (a) TRA-CER design and (b) TRA-2P design | Download Scientific Diagram
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet
The net clinical benefit of vorapaxar (CV death, MI, stroke or GUSTO... | Download Scientific Diagram
Vorapaxar - wikidoc
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
TRA 2°P-TIMI 50 – TIMI STUDY GROUP
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
![Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC](https://www.trc-canada.com/prod-img/V758202.png "Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC")
Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
IJMS | Free Full-Text | Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Chemical structure of vorapaxar. | Download Scientific Diagram
![PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c4d402004bb1cd7f7142aa35447751937911b5ff/2-Figure1-1.png "PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar")
PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar
